References
- Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer
drugs: the good, the bad and body-surface area. Eur J Cancer .
2002;38(13):1677-1684
- Kaestner SA, Sewell GJ. Chemotherapy dosing part I: scientific basis
for current practice and use of body surface area. Clin Oncol (R
Coll Radiol). 2007;19(1):23-37.
- Pinkel D. The use of body surface area as a criterion of drug dosage
in cancer chemotherapy. Cancer Res. 1958;18(7):853-856.
- Sawyer M, Ratain MJ. Body surface area as a determinant of
pharmacokinetics and drug dosing. Invest New Drugs.2001;19(2):171-177.
- Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in
dosing of investigational anticancer agents in adults, 1991-2001.J Natl Cancer Inst. 2002;94(24):1883-1888.
- Engels FK, Loos WJ, van der Bol JM, et al. Therapeutic drug monitoring
for the individualization of docetaxel dosing: a randomized
pharmacokinetic study. Clin Cancer Res. 2011;17(2): 353-362.
- Prado CMM, Baracos VE, McCargar LJ, et al. Body Composition as an
Independent Determinant of 5-Fluorouracil–Based Chemotherapy
Toxicity. Clin Cancer Res. 2007;13(11):3264-3268.
- Gibbs JP, Gooley T, Corneau B, et al. The impact of obesity and
disease on busulfan oral clearance in adults. Blood.1999;93(12):4436-4440.
- Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel.Clin Pharmacokinet. 1999;36(2):99-114.
- Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R.
Hepatic biotransformation of docetaxel (Taxotere) in vitro:
involvement of the CYP3A subfamily in humans. Cancer Res.1996;56(6):1296-1302.
- van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A.
Role of intestinal P-glycoprotein in the plasma and fecal disposition
of docetaxel in humans. Clin Cancer Res. 2000;6(7):2598-2603.
- Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of
docetaxel : recent developments. Clin Pharmacokinet.2006;45(3):235-252.
- Bruno R, Hille D, Riva A, et al. Population
pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in
patients with cancer. J Clin Oncol. 1998;16(1):187-196.
- Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage.
Implications for drug therapy. Clin Pharmacokinet.1994;26(4):292-307.
- Gusella M, Toso S, Ferrazzi E, Ferrari M, Padrini R. Relationships
between body composition parameters and fluorouracil pharmacokinetics.Br J Clin Pharmacol. 2002;54(2):131-139.
- Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate
size descriptors for dose calculation of anticancer drugs in the
obese. J Clin Oncol. 2007;25(30):4707-4713.
- Prado CM, Lima IS, Baracos VE, et al. An exploratory study of body
composition as a determinant of epirubicin pharmacokinetics and
toxicity. Cancer Chemother Pharmacol. 2011;67(1):93-101.
- Thompson PA, Rosner GL, Matthay KK, et al. Impact of body composition
on pharmacokinetics of doxorubicin in children: a Glaser Pediatric
Research Network study. Cancer Chemother Pharmacol.2009;64(2):243-251.
- Wong AL, Seng KY, Ong EM, et al. Body fat composition impacts the
hematologic toxicities and pharmacokinetics of doxorubicin in Asian
breast cancer patients. Breast Cancer Res Treat.2014;144(1):143-152.
- Sjøblom B, Grønberg BH, Benth JŠ, et al. Low muscle mass is associated
with chemotherapy-induced haematological toxicity in advanced
non-small cell lung cancer. Lung Cancer. 2015;90(1):85-91.
- Sjøblom B, Benth JŠ, Grønberg BH, et al. Drug Dose Per Kilogram Lean
Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet
Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Clin Lung
Cancer. 2017;18(2):e129-e136.
- Ali R, Baracos VE, Sawyer MB, et al. Lean body mass as an independent
determinant of dose-limiting toxicity and neuropathy in patients with
colon cancer treated with FOLFOX regimens. Cancer Med.2016;5(4):607-616.
- Cushen SJ, Power DG, Teo MY, et al. Body Composition by Computed
Tomography as a Predictor of Toxicity in Patients With Renal Cell
Carcinoma Treated With Sunitinib. Am J Clin Oncol.2017;40(1):47-52.
- Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE. Liver volume as a
determinant of drug clearance in children and adolescents. Drug
Metab Dispos. 1995;23(10):1110-1116.
- Nawaratne S, Brien JE, Seeman E, et al. Relationships among liver and
kidney volumes, lean body mass and drug clearance. Br J Clin
Pharmacol. 1998;46(5):447-452.
- Bruno R, Hille D, Riva A, et al. Population
pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in
patients with cancer. J Clin Oncol. 1998;16(1):187-196.
- Baille P, Bruno R, Schellens JH, et al. Optimal sampling strategies
for bayesian estimation of docetaxel (Taxotere) clearance. Clin
Cancer Res. 1997;3(9):1535-1538.
- Lin YS, Lockwood GF, Graham MA, et al. In-vivo phenotyping for CYP3A
by a single-point determination of midazolam plasma concentration.Pharmacogenetics. 2001;11(9):781-791.
- European Medicines Agency (2009) EMEA/CHMP/EWP/192217/2009 - Guidance
on Validation of Bioanalytical Methods. European Medicines Agency
Committee for Medicinal Products for Human Use.
- CTCAE 4.03. Common Terminology Criteria for Adverse Events (CTCAE).
Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010).
- Schorr M, Dichtel LE, Gerweck AV, et al. Sex differences in body
composition and association with cardiometabolic risk. Biol Sex
Differ. 2018;9(1):28. Published 2018 Jun 27.
- Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate Systemic Therapy
Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.J Clin Oncol. 2021;39(18):2037-2048.
- de Vries Schultink AHM, Crombag MBS, van Werkhoven E, et al.
Neutropenia and docetaxel exposure in metastatic castration-resistant
prostate cancer patients: A meta-analysis and evaluation of a clinical
cohort. Cancer Med. 2019;8(4):1406-1415.
- Bredella MA, Ghomi RH, Thomas BJ, et al. Comparison of DXA and CT in
the assessment of body composition in premenopausal women with obesity
and anorexia nervosa. Obesity (Silver Spring).2010;18(11):2227-2233.